company background image
935700

Gilead Sciences BRSE:000935700 Stock Report

Last Price

CHF79.01

Market Cap

CHF95.8b

7D

0%

1Y

5.3%

Updated

22 Jan, 2023

Data

Company Financials +

Gilead Sciences, Inc.

BRSE:000935700 Stock Report

Mkt Cap: CHF95.8b

935700 Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

935700 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends2/6

My Notes

New

Notes are coming soon

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$79.01
52 Week HighUS$82.53
52 Week LowUS$54.94
Beta0.43
1 Month Change0.053%
3 Month Change15.59%
1 Year Change5.34%
3 Year Change31.67%
5 Year Change3.95%
Change since IPO-26.23%

Recent News & Updates

Recent updates

Shareholder Returns

935700CH BiotechsCH Market
7D0%2.0%0.1%
1Y5.3%-70.2%-11.1%

Return vs Industry: 000935700 exceeded the Swiss Biotechs industry which returned -70.2% over the past year.

Return vs Market: 000935700 exceeded the Swiss Market which returned -11.1% over the past year.

Price Volatility

Is 935700's price volatile compared to industry and market?
935700 volatility
935700 Average Weekly Movementn/a
Biotechs Industry Average Movement7.0%
Market Average Movement4.0%
10% most volatile stocks in CH Market7.2%
10% least volatile stocks in CH Market2.0%

Stable Share Price: Insufficient data to determine 000935700's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine 000935700's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714,400Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
935700 fundamental statistics
Market CapCHF95.82b
Earnings (TTM)CHF3.07b
Revenue (TTM)CHF24.97b

31.2x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
935700 income statement (TTM)
RevenueUS$27.14b
Cost of RevenueUS$5.64b
Gross ProfitUS$21.50b
Other ExpensesUS$18.16b
EarningsUS$3.33b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 02, 2023

Earnings per share (EPS)2.66
Gross Margin79.22%
Net Profit Margin12.29%
Debt/Equity Ratio119.8%

How did 935700 perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

109%

Payout Ratio